Date: 2018-01-03
Type of information: Nomination
Compound: vice-president
Company: Anthera Pharmaceuticals (USA - CA)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On January 3, 2018, Anthera Pharmaceuticals announced the appointment of Patrick Murphy as senior vice president, manufacturing. Patrick brings over 35 years of experience in global manufacturing, product development, and process/analytical development to Anthera. In his new role, Patrick will oversee the manufacturing commercial scale-up of Sollpura®. Sollpura is currently in a Phase 3 study, “RESULT”, for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis.
- Most recently, Patrick served as vice president, mManufacturing at Versartis. Previously, he served as vice president of operations and site head at Solstice Neurosciences where he oversaw the worldwide supply and quality of Myobloc®/NeuroBloc® (Botulinum Toxin Type B) Injectable Solution. Patrick also served as Vice President of Chemistry, Manufacturing and Controls (CMC) and Operations at Acologix, Inc., Senior Vice President of Production Services of Abgenix Inc., and held various positions in manufacturing and operations at Genentech, including Director of Strategic Operations, over a 19-year period. Patrick holds a Bachelor of Science, Biochemistry from State University of New York, Binghamton.
Financial terms:
Latest news:
Is general: Yes
